For example, genetic editing to overexpress IL-37 may provide an approach to heighten the effectiveness and stability of mesenchymal stem cells (MSCs) in treating SLE (Xu et al., 2020b). The gene discussed is IL37; the disease is systemic lupus erythematosus.